INSM Q4 2025 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena

INSMInsmed Incorporated

$31B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$264M+152.6% YoY

Gross Profit

$218M82.5% margin

Operating Income

-$250M-94.6% margin

Net Income

-$328M-124.5% margin

EPS (Diluted)

$-1.54

QoQ Revenue Growth

+85.4%

Cash Flow

Operating Cash Flow

-$248M

Free Cash Flow

-$294M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.5B

Stockholders' Equity

$739M

Cash & Equivalents

$510M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$264M	$104M	+152.6%
Gross Profit	$218M	$78M	+178.0%
Operating Income	-$250M	-$230M	-8.4%
Net Income	-$328M	-$236M	-39.5%

Revenue Segments

Reportable Segment

$406M100%

Geographic Segments

UNITED STATES

$218M66%

Non-US

$113M34%